news
Nodality enters into a multi-year strategic collaboration with Pfizer in autoimmune disease
9 August 2012 | By Pfizer
Nodality, Inc.has announced a strategic collaboration with Pfizer Inc..
List view / Grid view
Pfizer
news
Pfizer reduces its greenhouse gas emissions by 20 percent
8 August 2012 | By Pfizer
Company reaches five-year public goal a year earlier than anticipated...
news
Pfizer announces resolutions with DOJ and SEC related to certain international operations
7 August 2012 | By Pfizer
U.S. agencies praise company’s cooperation and compliance program...
news
Pfizer announces co-primary clinical endpoints not met in second Phase 3 Bapineuzumab Study
6 August 2012 | By Pfizer
Bapineuzumab IV Phase 3 program discontinued...
news
Study shows Toviaz is effective in reducing urge urinary incontinence in patients with overactive bladder after suboptimal response to Detrol LA
3 August 2012 | By Pfizer
Phase 4 study has met its primary endpoint...
news
Pfizer announces positive top-line results from the ORAL Start Phase 3 study of Tofacitinib in RA
31 July 2012 | By Pfizer
Pfizer also provides update on Tofacitinib filing in the U.S.
news
Topline results of first of four studies in bapineuzumab Phase 3 program
23 July 2012 | By Pfizer
Co-primary clinical endpoints not met in study of patients with Alzheimer’s disease who carry the ApoE4 genotype...
news
Pfizer’s Crizotinib receives positive opinion for conditional marketing authorization from the CHMP
20 July 2012 | By Pfizer
“The CHMP’s positive opinion brings us a step closer..."
news
Pfizer and Northwestern University win LYRICA® patent case
19 July 2012 | By Pfizer
“The Court’s decision recognizes the infringement & validity of our LYRICA® patents..."
news
European Medicines Agency accepts regulatory submission for bazedoxifene/conjugated estrogens
19 July 2012 | By Pfizer
The EMA has accepted for review the MAA for bazedoxifene/conjugated estrogens...
article
Breaking old habits: Moving away from commonly used buffers in pharmaceuticals
10 July 2012 | By David Sek, Research Scientist, Pfizer
One of the key factors in stabilising proteins is determining the optimal pH and buffer system to provide adequate solubility and stability. Currently, three buffers, citrate, phosphate and acetate, make up the majority of buffers used in parenteral pharmaceuticals approved by the FDA, but less precedented excipients are certainly available…
article
Stem Cells In-Depth Focus 2012
In this Stem Cells In-Depth Focus: Stem cell therapies: Assuring safety; Role of pluripotent stem cells in neurotoxicology testing: Impacts and applied innovations...
news
Bristol-Myers Squibb & Pfizer receive response from FDA for ELIQUIS® (apixaban)
26 June 2012 | By Bristol-Myers Squibb Company / Pfizer
Additional information requested from ARISTOTLE trial results...
news
Pfizer statement regarding Prevnar 13® receiving ACIP recommendation for prevention of pneumococcal disease
20 June 2012 | By Pfizer
Pfizer issued the following statement...
news
Positive results from Phase 3 study PROFILE 1007 evaluating XALKORI® (crizotinib) in previously treated patients with ALK-Positive advanced NSCLC
19 June 2012 | By Pfizer
Detailed study results to be presented...
